Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Achaogen, Inc.AKAO · Entity 158957 | Chief Financial Officer | June 26, 2018 | June 28, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Achaogen, Inc.
Report date June 26, 2018 · Filed June 28, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 47,748 |
Last balance in matching sequence
After 2018-06-26 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-06-26 · Grant · Acquired 860 · Balance 48,046 F1: On February 8, 2018, the issuer granted the reporting person Restricted Stock Units ("RSUs") and a stock option that each vest upon the achievement of certain milestones. On June 26, 2018, one of the milestones was achieved, resulting in vesting of a portion of the RSUs and shares subject to the option. F2: Includes 31,730 RSUs. Row 2 · 2018-06-26 · Sale · Disposed 298 · Balance 47,748 F3: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of RSUs of the Issuer. F2: Includes 31,730 RSUs. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.64 · Expires 2028-02-08 | Direct | 4,000 |
Reported balance
After 2018-06-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-06-26 · Grant · Acquired 4,000 · Balance 4,000 F1: On February 8, 2018, the issuer granted the reporting person Restricted Stock Units ("RSUs") and a stock option that each vest upon the achievement of certain milestones. On June 26, 2018, one of the milestones was achieved, resulting in vesting of a portion of the RSUs and shares subject to the option. F4: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 8, 2018, the issuer granted the reporting person Restricted Stock Units ("RSUs") and a stock option that each vest upon the achievement of certain milestones. On June 26, 2018, one of the milestones was achieved, resulting in vesting of a portion of the RSUs and shares subject to the option.
F2: Includes 31,730 RSUs.
F3: The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of RSUs of the Issuer.
F4: The option is fully vested and exercisable.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Crinetics Pharmaceuticals, Inc.
Report date September 01, 2026 · Filed September 01, 2026
Section 16 reporting ended · disclosed 2026-09-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-01 · Disposition to issuer · Disposed 7,956 · Balance 71,471 F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Row 2 · 2026-09-01 · Disposition to issuer · Disposed 71,471 · Balance 0 F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.75 · Expires 2035-03-09 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-01 · Disposition to issuer · Disposed 80,000 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.79 · Expires 2036-02-23 | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-01 · Disposition to issuer · Disposed 50,000 · Balance 0 F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration").
F2: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding.
F3: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration.
F4: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options.
Revance Therapeutics, Inc.
Report date February 04, 2025 · Filed February 06, 2025
Section 16 reporting ended · disclosed 2025-02-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-02-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-02-04 · Other · Disposed 97,999 · Balance 103,555 F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Row 2 · 2025-02-06 · Disposition to issuer · Disposed 103,555 · Balance 0 F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement). Row 3 · 2025-02-06 · Grant · Acquired 20,883 · Balance 20,883 F3: Represents a deemed acquisition of the Shares underlying a portion of the performance-based restricted stock units ("PSUs") granted on January 31, 2023, pursuant to the terms of the Merger Agreement. Row 4 · 2025-02-06 · Disposition to issuer · Disposed 20,883 · Balance 0 F4: Pursuant to the Merger Agreement, each PSU award then outstanding and not vested was canceled and converted into the right to receive a lump sum cash payment, without interest thereon and subject to applicable withholding taxes, equal to the product of (i) the Per Share Price multiplied by (ii) the number of Shares subject to such PSU award (with the performance metrics deemed achieved as set forth in the Merger Agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer.
F2: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement).
F3: Represents a deemed acquisition of the Shares underlying a portion of the performance-based restricted stock units ("PSUs") granted on January 31, 2023, pursuant to the terms of the Merger Agreement.
F4: Pursuant to the Merger Agreement, each PSU award then outstanding and not vested was canceled and converted into the right to receive a lump sum cash payment, without interest thereon and subject to applicable withholding taxes, equal to the product of (i) the Per Share Price multiplied by (ii) the number of Shares subject to such PSU award (with the performance metrics deemed achieved as set forth in the Merger Agreement).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 1, 2026 20:53 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerStock Option (Right to Buy) · Derivative | 50,000 | $41.21 Strike: $43.79 | $2,060,500.00 |
DisclosureSEC source: 0001628280-26-059883 · wk-form4_1788296002.xml · derivative · entry 4 Schilke Tobin · CIK 0001678984 · Chief Financial & Infra. Ofcr. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2036-02-23 F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:53 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerStock Option (Right to Buy) · Derivative | 80,000 | $51.25 Strike: $33.75 | $4,100,000.00 |
DisclosureSEC source: 0001628280-26-059883 · wk-form4_1788296002.xml · derivative · entry 3 Schilke Tobin · CIK 0001678984 · Chief Financial & Infra. Ofcr. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2035-03-09 F3 · price: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · price: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. F3 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a "Company Stock Option"). Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration. F4 · derivative.exercise_date: The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:53 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerCommon Stock | 71,471 | $85.00 | $6,075,035.00 |
DisclosureSEC source: 0001628280-26-059883 · wk-form4_1788296002.xml · nonDerivative · entry 2 Schilke Tobin · CIK 0001678984 · Chief Financial & Infra. Ofcr. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a "Company RSU"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding. Read SEC document |
| September 01, 2026 Filed Sep 1, 2026 20:53 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | Disposition to issuerCommon Stock | 7,956 | $85.00 | $676,260.00 |
DisclosureSEC source: 0001628280-26-059883 · wk-form4_1788296002.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · Chief Financial & Infra. Ofcr. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,471 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the "Merger Agreement"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the "Company"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation ("Parent"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the "Merger"), effective as of September 1, 2026 (the "Effective Time"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the "Company Common Stock"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the "Merger Consideration"). Read SEC document |
| August 20, 2026 Filed Aug 24, 2026 20:52 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 471 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-058664 · wk-form4_1787604750.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · Chief Financial & Infra. Ofcr. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,427 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on September 1, 2027. F2 · balance_after: Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 22:43 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | SaleCommon Stock | 6,713 | $39.67 | $266,304.71 |
DisclosureSEC source: 0001628280-26-014772 · wk-form4_1772664230.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,121 F1 · kind: Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on March 10, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $39.67 per share. The range of sales prices on the transaction date was $39.67 to $39.74 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:36 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $43.79 | $0.00 |
DisclosureSEC source: 0001628280-26-011728 · wk-form4_1772055379.xml · derivative · entry 2 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-02-23 F3 · derivative.exercise_date: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 21:36 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 32,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011728 · wk-form4_1772055379.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,834 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027. F2 · balance_after: Includes 834 shares acquired under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantStock Option (Right to Buy) · Derivative | 80,000 | $0.00 Strike: $33.75 | $0.00 |
DisclosureSEC source: 0000950170-25-037200 · ownership.xml · derivative · entry 2 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2035-03-09 F2 · derivative.exercise_date: The option is exercisable as follows: 25% of the shares subject to the option vest on February 28, 2026, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 20:30 UTC | Crinetics Pharmaceuticals, Inc. CRNX · Entity 3579 | GrantCommon Stock | 52,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-037200 · ownership.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 F1 · price: The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2026. Read SEC document |
| February 06, 2025 Filed Feb 6, 2025 15:59 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Disposition to issuerCommon Stock | 20,883 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-015362 · ownership.xml · nonDerivative · entry 4 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the Merger Agreement, each PSU award then outstanding and not vested was canceled and converted into the right to receive a lump sum cash payment, without interest thereon and subject to applicable withholding taxes, equal to the product of (i) the Per Share Price multiplied by (ii) the number of Shares subject to such PSU award (with the performance metrics deemed achieved as set forth in the Merger Agreement). Read SEC document |
| February 06, 2025 Filed Feb 6, 2025 15:59 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 20,883 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-015362 · ownership.xml · nonDerivative · entry 3 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,883 F3 · shares: Represents a deemed acquisition of the Shares underlying a portion of the performance-based restricted stock units ("PSUs") granted on January 31, 2023, pursuant to the terms of the Merger Agreement. Read SEC document |
| February 06, 2025 Filed Feb 6, 2025 15:59 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Disposition to issuerCommon Stock | 103,555 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-015362 · ownership.xml · nonDerivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · price: Pursuant to the Merger Agreement, each Issuer restricted stock unit ("RSU") award then outstanding and not vested was canceled and converted into the right to receive an amount in cash, without interest thereon and subject to applicable withholding taxes, equal to the product of the Per Share Price and the total number of Shares subject to such unvested RSU award as of immediately prior to the Effective Time (as defined in the Merger Agreement). Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 15:59 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | OtherCommon Stock | 97,999 | $3.65 | $357,696.35 |
DisclosureSEC source: 0000950170-25-015362 · ownership.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,555 F1 · kind: The reported securities were disposed of pursuant to the terms of the Amended and Restated Agreement and Plan of Merger, dated as of December 7, 2024 (as subsequently amended, the "Merger Agreement"), by and among the Issuer, Crown Laboratories, Inc., a Delaware corporation ("Parent"), Reba Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub," and together with Parent, the "Buyer Parties"), pursuant to which Merger Sub completed a cash tender offer (the "Offer") for all of the issued and outstanding shares of common stock, par value $0.001 per share (the "Shares"), of the Issuer at a purchase price of $3.65 per share, without interest, and subject to any applicable withholding taxes (the "Per Share Price"). These Issuer Shares were tendered for purchase pursuant to the Offer. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 19:53 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 6,888 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-014824 · ownership.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,554 F1 · shares: Represents the vesting of performance-based restricted stock units (PSUs) granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. On February 3, 2025, the Issuer's Compensation Committee certified a portion of the PSUs eligible to vest based on (i) the achievement of a revenue goal, measured beginning January 1, 2024 through December 31, 2024, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 16:34 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 1,000 | $2.18 | $2,184.50 |
DisclosureSEC source: 0001479290-25-000005 · wk-form4_1735940046.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,666 F1 · shares: These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2024 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 30, 2024 Filed Jul 2, 2024 17:47 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 1,000 | $2.18 | $2,184.50 |
DisclosureSEC source: 0001479290-24-000103 · wk-form4_1719956817.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,666 F1 · shares: These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2024 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 18, 2024 Filed Mar 19, 2024 18:44 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 9,361 | $5.04 | $47,203.78 |
DisclosureSEC source: 0001479290-24-000066 · wk-form4_1710888231.xml · nonDerivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,666 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance-based restricted stock units ("PSUs") granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 18:44 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 3,822 | $5.31 | $20,275.71 |
DisclosureSEC source: 0001479290-24-000066 · wk-form4_1710888231.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,027 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the "RSA") for 7,540 shares. The RSA vested in three equal annual installments from March 15, 2021. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 16:44 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 17,447 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-24-000051 · wk-form4_1709588228.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,849 F1 · shares: Represents the vesting of performance-based restricted stock units (PSUs) granted on January 31, 2023, which vest over a three-year period based on the achievement of revenue goals. On February 29, 2024, the Issuer's Compensation Committee certified a portion of the PSUs eligible to vest based on (i) the achievement of a revenue goal, measured beginning January 1, 2023 through December 31, 2023, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date of March 15, 2024. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 16:46 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantPerformance Stock Units · Derivative | 145,001 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-24-000015 · wk-form4_1706910393.xml · derivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,001 Underlying: Common Stock · 145,001 shares Expires 2028-01-31 F2 · security: The performance-based RSUs (PSUs) granted to the reporting person on January 31, 2024, represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with the Company through the vesting dates. F2 · derivative.exercise_price: The performance-based RSUs (PSUs) granted to the reporting person on January 31, 2024, represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with the Company through the vesting dates. F3 · shares: The number of securities reported represents the maximum shares that can be earned. F2 · derivative.exercise_date: The performance-based RSUs (PSUs) granted to the reporting person on January 31, 2024, represent the right to receive, following vesting, a number of shares of Common Stock up to 150% of the number of PSUs. The number of shares of Common Stock acquired upon vesting of the PSUs is contingent upon the achievement of a preestablished performance metric, as approved by the Company's Compensation Committee, over a four-year performance period, subject to time based service requirements and continuous employment with the Company through the vesting dates. F3 · derivative.underlying_shares: The number of securities reported represents the maximum shares that can be earned. F3 · balance_after: The number of securities reported represents the maximum shares that can be earned. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 16:46 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 96,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-24-000015 · wk-form4_1706910393.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 188,402 F1 · shares: The shares subject to the Restricted Stock Unit shall vest in three (3) equal annual installments beginning from February 15, 2025, subject to the reporting person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date. Read SEC document |
| December 31, 2023 Filed Jan 3, 2024 16:48 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 434 | $7.47 | $3,241.98 |
DisclosureSEC source: 0001479290-24-000005 · wk-form4_1704318504.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,735 F1 · shares: These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2023 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 16:16 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 11,215 | $18.91 | $212,075.65 |
DisclosureSEC source: 0001479290-23-000099 · wf-form4_169213053920271.xml · nonDerivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,301 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 11, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the PSA. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 16:16 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 22,620 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-23-000099 · wf-form4_169213053920271.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,516 F1 · shares: Represents the vesting of a performance-based restricted stock award (PSA) granted on February 2, 2021. On August 11, 2023, the Issuer's Compensation Committee certified 100% of the PSAs eligible to vest based on (i) the achievement of a cumulative revenue goal, calculated in accordance with GAAP, adjusted to exclude revenue recognized from collaboration agreements and classified as collaboration revenue, measured beginning on January 1, 2021, provided the goal is achieved on or before the three-year anniversary of the U.S. Food and Drug Administration's approval of the Issuer's biologics license application for DAXXIFY(R) for the improvement of glabellar lines, and (ii) subject to the Reporting Person remaining in continuous service through the vesting date. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 21:11 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 1,701 | $25.04 | $42,593.04 |
DisclosureSEC source: 0001479290-23-000083 · wf-form4_168860588867593.xml · nonDerivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,896 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke. Read SEC document |
| June 30, 2023 Filed Jul 5, 2023 21:11 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 769 | $15.61 | $12,001.01 |
DisclosureSEC source: 0001479290-23-000083 · wf-form4_168860588867593.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,597 F1 · kind: These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2023 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 18:06 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 500 | $31.00 | $15,500.00 |
DisclosureSEC source: 0001479290-23-000077 · wf-form4_168600274920722.xml · nonDerivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,828 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 18:06 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 2,701 | $30.57 | $82,569.57 |
DisclosureSEC source: 0001479290-23-000077 · wf-form4_168600274920722.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,328 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke. Read SEC document |
| May 15, 2023 Filed May 16, 2023 20:29 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 21,401 | $34.55 | $739,338.21 |
DisclosureSEC source: 0001479290-23-000075 · wf-form4_168428336033050.xml · nonDerivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,029 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: The price reported in Table 1, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.01 to $34.55. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2023 Filed May 2, 2023 16:01 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 3,201 | $31.70 | $101,471.70 |
DisclosureSEC source: 0001479290-23-000056 · wf-form4_168305767740098.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,081 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 16:24 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 3,201 | $32.15 | $102,912.15 |
DisclosureSEC source: 0001479290-23-000053 · wf-form4_168063984837857.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,282 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 15:21 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 3,739 | $30.65 | $114,600.35 |
DisclosureSEC source: 0001479290-23-000041 · wf-form4_167908089885096.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,483 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of a restricted stock award (the"RSA") for 7,540 shares. The RSA vests in three equal annual installments from March 15, 2021. Read SEC document |
| March 09, 2023 Filed Mar 9, 2023 21:46 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 18,517 | $31.59 | $584,883.52 |
DisclosureSEC source: 0001479290-23-000036 · wf-form4_167841635608608.xml · nonDerivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,222 F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PSUs. This sale is mandated by the Issuer's sell to cover agreement that requires the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:25 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 3,201 | $33.50 | $107,233.50 |
DisclosureSEC source: 0001479290-23-000031 · wf-form4_167781034001694.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,390 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke. Read SEC document |
| February 15, 2023 Filed Feb 16, 2023 20:28 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 2,085 | $33.21 | $69,242.85 |
DisclosureSEC source: 0001479290-23-000018 · wf-form4_167659730390739.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,591 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award (the "RSA") for 5,500 shares. The RSA vested in three equal annual installments from February 15, 2020. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 21:38 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 3,201 | $34.60 | $110,754.60 |
DisclosureSEC source: 0001479290-23-000015 · wf-form4_167539188027302.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,676 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke. F2 · balance_after: Includes 2,953 shares purchased pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:38 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,435 | $0.00 Strike: $34.68 | $0.00 |
DisclosureSEC source: 0001479290-23-000015 · wf-form4_167539188027302.xml · derivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,435 Underlying: Common Stock · 50,435 shares Expires 2033-01-30 F3 · derivative.exercise_date: The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from January 31, 2023, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date. Read SEC document |
| January 20, 2023 Filed Jan 23, 2023 17:35 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 1,000 | $31.00 | $31,000.00 |
DisclosureSEC source: 0001479290-23-000012 · wf-form4_167451332217569.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,877 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke. F2 · balance_after: Includes 3,716 shares purchased pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| January 09, 2023 Filed Jan 10, 2023 20:06 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 1,000 | $30.00 | $30,000.00 |
DisclosureSEC source: 0001479290-23-000007 · wf-form4_167339919617880.xml · nonDerivative · entry 3 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,877 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke. Read SEC document |
| January 09, 2023 Filed Jan 10, 2023 20:06 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 1,000 | $28.00 | $28,000.00 |
DisclosureSEC source: 0001479290-23-000007 · wf-form4_167339919617880.xml · nonDerivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,877 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke. Read SEC document |
| January 09, 2023 Filed Jan 10, 2023 20:06 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | SaleCommon Stock | 1,701 | $25.00 | $42,525.00 |
DisclosureSEC source: 0001479290-23-000007 · wf-form4_167339919617880.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,877 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke. Read SEC document |
| December 31, 2022 Filed Jan 3, 2023 16:29 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 645 | $12.18 | $7,856.42 |
DisclosureSEC source: 0001479290-23-000003 · wf-form4_167278132182264.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,578 F1 · kind: These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2022 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| December 15, 2022 Filed Dec 16, 2022 16:12 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 1,557 | $21.50 | $33,475.50 |
DisclosureSEC source: 0001479290-22-000106 · wf-form4_167122509909406.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,933 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on December 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award ("RSA") for 4,500 shares. The RSA vests in four equal annual installments from December 15, 2018, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Inducement Plan) on each vesting date. Read SEC document |
| September 22, 2022 Filed Mar 9, 2023 21:46 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 42,349 | $0.00 | $0.00 |
DisclosureSEC source: 0001479290-23-000036 · wf-form4_167841635608608.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,739 F1 · kind: Represents settlement of a performance-based restricted stock unit ("PSU") granted on February 2, 2022. On September 22, 2022, the Company's Compensation Committee certified 100% of the PSUs eligible to vest based on i) the achievement of the U.S. Food and Drug Administration's ("FDA") approval of the Issuer's biologics license application (BLA) for DAXXIFY(R) for the improvement of glabellar lines ("FDA Approval") and ii) subject to the Reporting Person remaining in continuous service through the six-month anniversary following the date of the FDA Approval which six-month anniversary was March 7, 2023. Read SEC document |
| June 30, 2022 Filed Jul 5, 2022 18:15 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantCommon Stock | 965 | $11.75 | $11,335.86 |
DisclosureSEC source: 0001479290-22-000072 · wf-form4_165705928528709.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,490 F1 · kind: These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on June 30, 2022 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| March 15, 2022 Filed Mar 17, 2022 17:48 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 2,607 | $15.79 | $41,164.53 |
DisclosureSEC source: 0001209191-22-019713 · doc4.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,525 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the "RSA") for 22,620 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 20:49 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 683 | $13.35 | $9,118.05 |
DisclosureSEC source: 0001479290-22-000021 · wf-form4_164514894332397.xml · nonDerivative · entry 2 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,132 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of an RSA for 5,000 shares. The RSA vests in three equal annual installments from February 15, 2019, subject to Mr. Schilke's Continuous Service (as defined in the Plan) on each vesting date. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 20:49 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | Tax withholdingCommon Stock | 2,241 | $13.35 | $29,917.35 |
DisclosureSEC source: 0001479290-22-000021 · wf-form4_164514894332397.xml · nonDerivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,815 F1 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award ("RSA") for 16,500 shares. The RSA vests in three equal annual installments from February 15, 2020, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan.")) on each vesting date. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 20:31 UTC | Revance Therapeutics, Inc. RVNC · Entity 83521 | GrantEmployee Stock Option (Right to Buy) · Derivative | 68,093 | $0.00 Strike: $13.08 | $0.00 |
DisclosureSEC source: 0001479290-22-000014 · wf-form4_164402470162531.xml · derivative · entry 1 Schilke Tobin · CIK 0001678984 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,093 Underlying: Common Stock · 68,093 shares Expires 2032-02-01 F1 · derivative.exercise_date: The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 2, 2022, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.